RA Capital Management’s Travere Therapeutics TVTX Stock Holding History

RA Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.2M	Buy	+746,841	New	+$22.3M	0.24%	55
2025 Q4	–	Sell	-1,150,000	Closed	-$27.5M	–	87
2025 Q3	$27.5M	Hold	1,150,000	–	–	0.34%	38
2025 Q2	$17M	Hold	1,150,000	–	–	0.29%	39
2025 Q1	$20.6M	Hold	1,150,000	–	–	0.34%	41
2024 Q4	$20M	Buy	+1,150,000	New	+$20.3M	0.27%	56
2023 Q1	–	Sell	-3,984,681	Closed	-$83.8M	–	69
2022 Q4	$83.8M	Sell	3,984,681 -938,260	-19%	-$19.9M	1.7%	22
2022 Q3	$121M	Hold	4,922,941	–	–	2.59%	8
2022 Q2	$119M	Hold	4,922,941	–	–	3.18%	6
2022 Q1	$127M	Sell	4,922,941 -691,487	-12%	-$18.4M	2.77%	6
2021 Q4	$174M	Hold	5,614,428	–	–	3.07%	4
2021 Q3	$136M	Hold	5,614,428	–	–	1.89%	17
2021 Q2	$81.9M	Hold	5,614,428	–	–	1.31%	24
2021 Q1	$140M	Buy	5,614,428 +1,056,561	+23%	+$29.2M	2.11%	12
2020 Q4	$124M	Sell	4,557,867 -77,820	-2%	-$1.82M	1.74%	15
2020 Q3	$85.6M	Hold	4,635,687	–	–	1.57%	21
2020 Q2	$94.6M	Buy	4,635,687 +469,234	+11%	+$7.47M	1.84%	21
2020 Q1	$60.8M	Sell	4,166,453 -86,000	-2%	-$1.29M	1.92%	20
2019 Q4	$60.4M	Buy	4,252,453 +264,893	+7%	+$3.38M	1.83%	16
2019 Q3	$46.2M	Buy	+3,987,560	New	+$65.9M	2.75%	11

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RA Capital Management's TVTX Position: Q1 2026 in Review

RA Capital Management opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 746,841 shares worth $22.2M. The stake represents 0.24% of the portfolio and ranks #55 among its holdings. This is a return to the name: RA Capital Management previously reported a position in TVTX as recently as Q3 2025.

RA Capital Management first reported a position in TVTX in Q3 2019 and has held it in 19 quarters since. The position peaked at $174M in Q4 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

RA Capital Management held 746,841 shares of Travere Therapeutics worth $22.2M as of Q1 2026.
Travere Therapeutics was a new RA Capital Management position in Q1 2026.
Travere Therapeutics made up 0.24% of RA Capital Management's portfolio in Q1 2026, its #55 holding.
RA Capital Management first reported a position in Travere Therapeutics in Q3 2019 and has held it in 19 quarters since.
RA Capital Management's Travere Therapeutics position peaked at $174M in Q4 2021.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.